HOME >> BIOLOGY >> NEWS
New bipolar survey: Patients' satisfaction influenced

Vienna, June 29th 2005 Preliminary results from a large-scale global study of people living with bipolar disorder,1 presented today at the World Congress of Biological Psychiatry (WCBP), found that patient satisfaction with treatment is achieved through combining broad-based efficacy with a favourable tolerability profile.

The Thinking Ahead Survey,1 included 687 bipolar patients from seven countries (UK, US, Germany, Italy, Canada, Spain and Greece). These preliminary results indicate that:

  • 88% of respondents said drug treatment satisfaction is largely influenced by how effective it is, followed then by patients experiencing few or manageable side effects (77%)

  • 79% of respondents believe that a successful treatment would be one which leads to significant quality of life changes in terms of increased functionality and improved lifestyle

Bipolar disorder, also known as manic-depressive illness, is a severe biological disorder that affects approximately 3-4% of the adult population.5,6 More than half of those with bipolar disorder stop taking their medication at some point during their illness, subjecting themselves to a high risk of relapse and an increased risk of suicide.7

"As someone who lives with bipolar disorder I need a treatment which can control the manic symptoms but also treat the more disabling depressive symptoms," comments Michael Grinter, SEROQUEL patient and Thinking Ahead Taskforce member. "The treatment that I am currently taking, SEROQUEL, has brought an enormous benefit to my life in terms of controlling both poles of my mood and has enabled me to return to work and live a fully functioning life. It has provided me with the confidence to enjoy each day again."

Recently-published SEROQUEL (quetiapine) data in the Journal of Current Medical Research and Opinion confirm SEROQUEL's efficacy and tolerability in the treatment of bipolar mania symp
'"/>

Contact: Lisa O'Sullivan
lisa.o'sullivan@shirehealthinternational.com
44-207-108-6515
Shire Health International
29-Jun-2005


Page: 1 2 3

Related biology news :

1. New databases put wings on search for bipolar risk genes
2. $9M grant awarded to University of Cincinnati for bipolar disorder research
3. Genetic roots of bipolar disorder revealed by first genome-wide study of illness
4. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
5. Gene controlling circadian rhythms may be involved in onset of bipolar disorder
6. Extreme irritability -- is it childhood bipolar disorder?
7. Fear circuit flares as bipolar youth misread faces
8. Clock molecules sensitivity to lithium sheds light on bipolar disorder
9. Link suggested between regions on two chromosomes and bipolar disorder
10. Research zeros in on bipolar disorder genes, link with thyroid condition
11. Beyond lithium for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
Cached News: